Swiss National Bank’s Coherus Oncology CHRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-196,000
| Closed | -$653K | – | 2508 |
|
|
2023
Q4 | $653K | Sell |
196,000
-13,100
| -6% | -$35.1K | ﹤0.01% | 2426 |
|
|
2023
Q3 | $782K | Buy |
209,100
+29,800
| +17% | +$138K | ﹤0.01% | 2374 |
|
|
2023
Q2 | $766K | Buy |
179,300
+45,000
| +34% | +$266K | ﹤0.01% | 2432 |
|
|
2023
Q1 | $919K | Sell |
134,300
-15,900
| -11% | -$123K | ﹤0.01% | 2302 |
|
|
2022
Q4 | $1.19M | Buy |
150,200
+3,300
| +2% | +$25.4K | ﹤0.01% | 2251 |
|
|
2022
Q3 | $1.41M | Buy |
146,900
+1,700
| +1% | +$17.2K | ﹤0.01% | 2115 |
|
|
2022
Q2 | $1.05M | Hold |
145,200
| – | – | ﹤0.01% | 2331 |
|
|
2022
Q1 | $1.88M | Buy |
145,200
+11,300
| +8% | +$144K | ﹤0.01% | 2072 |
|
|
2021
Q4 | $2.14M | Hold |
133,900
| – | – | ﹤0.01% | 2016 |
|
|
2021
Q3 | $2.15M | Buy |
133,900
+5,500
| +4% | +$80.6K | ﹤0.01% | 2004 |
|
|
2021
Q2 | $1.78M | Sell |
128,400
-3,300
| -3% | -$46.7K | ﹤0.01% | 2189 |
|
|
2021
Q1 | $1.92M | Buy |
131,700
+3,100
| +2% | +$52.6K | ﹤0.01% | 2027 |
|
|
2020
Q4 | $2.23M | Hold |
128,600
| – | – | ﹤0.01% | 1833 |
|
|
2020
Q3 | $2.36M | Buy |
128,600
+3,400
| +3% | +$63.3K | ﹤0.01% | 1637 |
|
|
2020
Q2 | $2.24M | Buy |
125,200
+23,200
| +23% | +$393K | ﹤0.01% | 1651 |
|
|
2020
Q1 | $1.65M | Buy |
102,000
+1,900
| +2% | +$35.1K | ﹤0.01% | 1565 |
|
|
2019
Q4 | $1.8M | Buy |
100,100
+2,400
| +2% | +$44.3K | ﹤0.01% | 1787 |
|
|
2019
Q3 | $1.98M | Buy |
97,700
+2,800
| +3% | +$55.9K | ﹤0.01% | 1660 |
|
|
2019
Q2 | $2.1M | Buy |
94,900
+14,300
| +18% | +$248K | ﹤0.01% | 1665 |
|
|
2019
Q1 | $1.1M | Buy |
80,600
+2,600
| +3% | +$34.7K | ﹤0.01% | 2009 |
|
|
2018
Q4 | $706K | Buy |
78,000
+3,900
| +5% | +$45.1K | ﹤0.01% | 2197 |
|
|
2018
Q3 | $1.22M | Buy |
74,100
+3,600
| +5% | +$63.8K | ﹤0.01% | 2028 |
|
|
2018
Q2 | $987K | Buy |
70,500
+5,000
| +8% | +$71.6K | ﹤0.01% | 2165 |
|
|
2018
Q1 | $724K | Buy |
65,500
+7,800
| +14% | +$85.3K | ﹤0.01% | 2263 |
|
|
2017
Q4 | $508K | Buy |
57,700
+5,500
| +11% | +$58.9K | ﹤0.01% | 2405 |
|
|
2017
Q3 | $697K | Hold |
52,200
| – | – | ﹤0.01% | 2256 |
|
|
2017
Q2 | $749K | Hold |
52,200
| – | – | ﹤0.01% | 2226 |
|
|
2017
Q1 | $1.1M | Buy |
52,200
+14,900
| +40% | +$367K | ﹤0.01% | 1959 |
|
|
2016
Q4 | $1.05M | Hold |
37,300
| – | – | ﹤0.01% | 2001 |
|
|
2016
Q3 | $999K | Hold |
37,300
| – | – | ﹤0.01% | 1971 |
|
|
2016
Q2 | $630K | Buy |
37,300
+8,500
| +30% | +$160K | ﹤0.01% | 2227 |
|
|
2016
Q1 | $591K | Buy |
28,800
+5,300
| +23% | +$86.8K | ﹤0.01% | 2212 |
|
|
2015
Q4 | $540K | Buy |
23,500
+5,600
| +31% | +$144K | ﹤0.01% | 2214 |
|
|
2015
Q3 | $359K | Buy |
17,900
+9,700
| +118% | +$295K | ﹤0.01% | 2332 |
|
|
2015
Q2 | $237K | Buy |
+8,200
| New | +$207K | ﹤0.01% | 2514 |
|
Other funds holding CHRS
RCMNY
KKRC
Swiss National Bank's CHRS Position: Q1 2024 in Review
Swiss National Bank sold out of Coherus Oncology (CHRS) in Q1 2024, closing a stake of 196,000 shares — an estimated $653K sold.
Swiss National Bank first reported a position in CHRS in Q2 2015 and held it in 35 quarters. The position peaked at $2.36M in Q3 2020. 137 funds tracked by Wall St. Rank hold CHRS as of Q1 2024.
- Swiss National Bank reported no remaining Coherus Oncology position as of Q1 2024 after selling out during the quarter.
- Swiss National Bank sold 196,000 Coherus Oncology shares in Q1 2024, an estimated $653K.
- Swiss National Bank first reported a position in Coherus Oncology in Q2 2015 and held it in 35 quarters.
- Swiss National Bank's Coherus Oncology position peaked at $2.36M in Q3 2020.
- 137 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2024.
Based on Swiss National Bank's 13F filing for Q1 2024, filed 7 May 2024.